A position as a Research Assistant Professor is available to study the pathobiology of leukemia, including acute myeloid leukemia (AML) and T cell acute lymphoblastic leukemia (T-ALL), as well as the discovery and validation of new therapy targets to treat relapsed/refractory AML and T-ALL the pathobiology of leukemia, including acute myeloid leukemia (AML) and T cell acute lymphoblastic leukemia (T-ALL), as well as the discovery and validation of new therapy targets to treat relapsed/refractory AML and T-ALL in the laboratory of Dr. Michael Deininger at the University of Michigan Medical School.
Projects funded by the NIH and other sources include: (1) Clonal dynamics of aggressive systemic mastocytosis on avapritinib therapy; (2) Strategies to target BCR-ABL1 compound mutants in CML and Ph+ ALL and translating these findings to the clinic. Successful candidates will strengthen the translational research program in hematologic malignancies within the University of Michigan Department of Medicine/Division of Hematology and Oncology, and the Rogel Cancer Center. The successful candidate will strengthen the translational research program in hematologic malignancies within the University of Michigan Department of Medicine/Division of Hematology/Oncology and the Rogel Cancer Center.